Tirzepatide currently being a dual GLP-1 and GIP agonist, it truly is proposed the GIP part of dual agonism could be responsible for the additional profit, given the probable advantage of GIP receptor agonism on peripheral insulin sensitization. As a result, tirzepatide was more practical than dulaglutide in reducing fasting dietary TAG [6,seven].